REGN

Regeneron Pharmaceuticals Bolsa (NASDAQ: REGN)

Últimas noticias sobre Regeneron Pharmaceuticals (NASDAQ:REGN) Bolsa

REGENERON PHARMACEUTICALS

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Medical,Billing,Document,And,Dollar,Banknote,,Calculator,,Stathoscope.,Medical,Treatment

Health Care

Markets

AMGN

RHHBY

Trump anuncia una orden ejecutiva para reducir precios de medicamentos hasta un 80 %, aplicando la política de &#34;Nación Más Favorecida&#34;.

Trump firma orden ejecutiva histórica para reducir precios de medicamentos en EE. UU.

Eli Lilly and Co.

Equities

Government

News

ABBV

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals Inc

Regnum Corp

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals has a market capitalization of $55.03 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 20 years ago, it would be worth $6,185.92 today based on a price of $509.72 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750453216_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Dupixent&nbsp;(dupilumab) for adult patients with bullous pemphigoid (BP), a rare, chronic <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">autoimmune skin disorder</a>.
BP primarily affects elderly patients and is characterized by intense itch, painful blisters and lesions, and skin reddening. It can be chronic and relapsing with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46019439/dupixent-dupilumab-approved-in-the-u-s-as-the-only-targeted-medicine-to-treat-patients-with-bullou" rel="noreferrer noopener">underlying type 2 inflammation</a>.
The blisters and rash can form over much of the body and cause the skin to bleed and break down, making patients more prone to infection.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a>
The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP.
Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS).
During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained.
The FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are:
<ul class="wp-block-list">
<li>18.3% of patients experienced sustained disease remission compared to 6.1%, the primary endpoint.</li>
<li>38.3% of patients achieved clinically meaningful itch reduction compared to 10.5%.</li>
<li>The median cumulative OCS dose was 2.8 grams compared to 4.1 grams.</li>
</ul>
In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections, and keratitis.
Additionally, one acute generalized exanthematous pustulosis was reported in 1 patient treated with Dupixent and zero treated with placebo.
In April, the FDA approved Dupixent&nbsp;for adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-d" rel="noreferrer noopener">antihistamine treatment</a>.
Price Action: REGN stock closed at $513.58 on Wednesday. SNY stock is up 1.45% at $48.31&nbsp;during the premarket session at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response" target="_blank" rel="noreferrer noopener">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a></li>
</ul>
Image: Shutterstock

Biotech

Large Cap

General

FDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent&#xAE; (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP).
BP primarily affects elderly patients, and is characterized by intense itch, painful blisters and lesions, as well as reddening of the skin. It can be chronic and relapsing with underlying type 2 inflammation. The blisters and rash can form over much of the body and cause the skin to bleed and break down, resulting in patients being more prone to infection and affecting their daily functioning. Available treatment options are limited and can add to overall disease burden by suppressing a patient's immune system.
"People affected by bullous pemphigoid endure unrelenting itch and painful blisters that can damage the skin. Until now, these primarily elderly patients have had limited therapeutic options available, with potential side effects that have often added to their burden," Patrick Dunn, Executive Director at the International Pemphigus and Pemphigoid Foundation. "The approval of Dupixent for bullous pemphigoid brings a novel treatment approach to patients and their caregivers, and we are grateful for the tireless efforts of the scientific community who helped us reach this critical milestone."
"Today's approval extends the remarkable ability of Dupixent to transform treatment paradigms for people living with a variety of diseases with underlying type 2 inflammation, from common conditions like asthma and atopic dermatitis, to rarer ones such as eosinophilic esophagitis and prurigo nodularis, and now including bullous pemphigoid," said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. "Dupixent has shown the potential to improve the most challenging effects of bullous pemphigoid, while helping some patients achieve sustained disease remission and decreased oral corticosteroid use. Additionally, this approval further reinforces the demonstrated safety profile of Dupixent in a broad age range of patients, from infants to elderly people, and across dermatological, respiratory and gastrointestinal diseases."
The FDA approval is based on data from the pivotal ADEPT Phase 2/3 trial that evaluated the efficacy and safety of Dupixent compared to placebo in adults with moderate-to-severe BP. Patients were randomized to receive Dupixent 300 mg (n=53) or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained. During the FDA review, the analyses were updated; the FDA-approved results at 36 weeks in the label for Dupixent compared to placebo are:
<ul>
<li>18.3% of patients experienced sustained disease remission compared to 6.1% (12.2% difference; 95% confidence interval: -0.8% to 26.1%), the primary endpoint</li>
<li>38.3% of patients achieved clinically meaningful itch reduction compared to 10.5%</li>
<li>Median cumulative OCS dose was 2.8 grams compared to 4.1 grams &nbsp;</li>
</ul>
In this elderly population, the most common adverse events (≥2%) more frequently observed in patients on Dupixent compared to placebo were arthralgia, conjunctivitis, blurred vision, herpes viral infections and keratitis. Additionally, 1 case of acute generalized exanthematous pustulosis was reported in 1 patient treated with Dupixent and 0 patients treated with placebo.

Regulations

Regeneron and Sanofi Win FDA Approval for Dupixent to Treat Painful Skin Disease in Elderly Patients

Scholar Rock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-<a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">induced weight loss</a>.
Tirzepatide is an active ingredient in Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) widely used Mounjaro and Zepbound for diabetes and weight loss, respectively.
The trial demonstrated that 30% of the total weight loss with tirzepatide alone was <a href="https://www.benzinga.com/pressreleases/25/06/b45991772/scholar-rock-reports-positive-phase-2-embraze-trial-results-demonstrating-statistically-significan" target="_blank" rel="noreferrer noopener">due to lean mass loss</a>.
Apitegromab therapy (10 mg/kg) with tripeptide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tripeptide alone, leading to higher-quality weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44359926/scholar-rock-stock-jumps-on-additional-data-from-pivotal-trial-of-muscular-dystrophy-treatment" rel="noreferrer noopener">Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment</a>
The study showed that 30.2% of the total weight loss with tirzepatide, the ingredient in Zepbound, was due to lean mass loss.
According to 24-week data, adding 10 mg/kg apitegromab therapy to the tripeptide regimen halved the proportion of lean mass lost to 14.6%.
The company described the apitegromab-tirzepatide combo as "higher quality of weight loss." Specifically, these patients lost 85% and 15% of their fat and lean mass, respectively, while the ratio for the&nbsp;tirzepatide-placebo cohort was 70% and 30%.
Regarding total weight loss, patients on apitegromab-tirzepatide saw their weight drop by 12.3% compared to 13.4% for those on tirzepatide-placebo.
Apitegromab with tirzepatide was generally well tolerated by participants.
Earlier in June, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)&nbsp;released interim results from the ongoing Phase 2 COURAGE trial investigating combinations of&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) (GLP-1&nbsp;receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass.
Last week, Juvena Therapeutics Inc. announced global licensing and&nbsp;multi-target research collaboration&nbsp;with&nbsp;Eli Lilly. The two companies aim to develop and commercialize drug candidates that improve&nbsp;<a href="https://www.benzinga.com/news/health-care/25/06/45887444/eli-lilly-inks-pact-with-juvena-therapeutics-to-develop-muscle-boosting-drugs" target="_blank" rel="noreferrer noopener">muscle health and body composition</a>.
Price Action: SRRK stock is up 18% at $36.77 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a></li>
</ul>
Photo: Shutterstock

Movers

SRRK

Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study

23ANDME HOLDING CO A by 23andMe Holding Co.

MEHCQ

Reuters Cites Regeneron Pharmaceuticals On 23andme Bid Saying Declined To Submit A New Bid Exceeding Original Winning Bid Of $256M

Deep Apple Therapeutics, Inc. announced on Wednesday a research collaboration and exclusive worldwide license agreement with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">including obesity</a>.
Under the terms of the agreement, Deep Apple <a target="_blank" href="https://deepappletx.com/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases/" rel="noreferrer noopener">will</a> discover and optimize compounds using its proprietary drug discovery platform, which combines machine-learning-powered virtual screening with structural biology enabled by cryo-electron microscopy (cryo-EM) to dramatically improve speed, quality, and novelty in lead generation and optimization.
Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" rel="noreferrer noopener">Novo Nordisk&#8217;s Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say</a>
Both companies will collaborate on the research plan, with program handoff to Novo Nordisk occurring immediately before the start of IND-enabling studies.
Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk.
Deep Apple will be eligible to receive up to $812 million in payments and potential royalties on sales of any products that emerge from the collaboration.
Recently, the Danish pharma giant <a target="_blank" href="https://clinicaltrials.gov/study/NCT07011667?cond=CAGRISEMA&amp;sort=StudyFirstPostDate&amp;rank=1" rel="noreferrer noopener">initiated</a> a Phase 3 trial to evaluate the efficacy and safety of cagrilintide sc combined with semaglutide sc (CagriSema&nbsp;sc) once weekly for weight management and long-term weight maintenance in obese participants.
The two-part study in around 600 participants will last about 3 years and 3 months.
In March, Novo Nordisk announced headline results from the REDEFINE 2 phase 3 trial in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44244966/novo-nordisks-combo-drug-cagrisema-shows-16-weight-reduction-in-second-phase-3-trial-stock-falls" rel="noreferrer noopener">global REDEFINE program</a>.
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema compared to placebo.
After 68 weeks, 61.9% of patients treated with CagriSema were on the highest dose.
When evaluating treatment effects, if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 15.7% after 68 weeks compared to 3.1% with placebo.
Last week, Regeneron Pharmaceuticals, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) released interim results from the ongoing Phase 2 COURAGE trial evaluating Regeneron&#8217;s trevogrumab (anti-GDF8/anti-myostatin) with semaglutide (GLP-1&nbsp;receptor agonist) with or without garetosmab&nbsp;<a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to the loss of lean mass.
Price Action: NVO stock is up 0.04% at $79.36&nbsp;at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45834370/eli-lillys-obesity-drug-success-spurs-japanese-biotechs-anti-muscle-wasting-combo-therapy" target="_blank" rel="noreferrer noopener">Eli Lilly&#8217;s Obesity Drug Success Spurs Japanese Biotech&#8217;s Anti-Muscle-Wasting Combo Therapy</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Contracts

Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies

REGN climbs over 16 points after the alert
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/09204238/Screenshot-2025-06-09-at-4.39.08%E2%80%AFPM-994x1024.png" alt="" class="wp-image-14161" /></figure>
Regeneron Pharma Inc. (REGN) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:16AM on June 9th, a significant trading signal occurred for Regeneron Pharma Inc., (REGN) as it demonstrated a Power Inflow at a price of $501.83. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Regeneron&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Regeneron's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for REGN, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_June2025</a>, which are responsible for parts of the data within this article.
The price at the time of the Power Inflow was $501.83. The returns on the High price ($517.91) and Close price ($517.60) after the Power Inflow are respectively 3.2% and 3.1%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. They were very close today, but that is not always the case.
Past performance is not indicative of future results

Technicals

Opinion

Signals

Regeneron Pharma Shares Rise Over 3% After Key Signal

WIIM

Regeneron Pharmaceuticals shares are trading higher. A company executive reportedly said the 23andMe auction process was recently reopened and that the tariff situation is not "material" to the business.

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $950 to $800.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $800

<a href="https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference" title="https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference">https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference</a>

Global

Watching Regeneron; At Goldman Sachs Conference, Exec Reportedly Says 23andMe Auction Process Was Recently Reopened And Is "Fairly Complicated"; Says Tariff Situation Currently Enacted Is Not "Material" To Business, But Sectoral Tariffs Could Have An Impact

French drugmaker Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">runs through March</a>.
Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023.
Immunizations <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-09-05-00-00-3095598" rel="noreferrer noopener">begin</a> in early fall. The current supply for the upcoming season matches the total doses distributed last year, and production continues.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Sanofi said Beyfortus duration of protection was extended for six months in the EU. This year&#8217;s EU shipments are marked by an important change to the Beyfortus EU label, extending the duration of protection through six months so Beyfortus can continue to offer season-long protection for all infants, including older babies immunized just before the RSV season begins.
More than six million babies have been immunized worldwide, and millions more will be immunized this season in more than 40 countries to help protect them from the potentially devastating impact of RSV disease.
In another development, Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi on Saturday presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent&nbsp;(dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45828306/dupixent-dupilumab-data-at-revolutionizing-atopic-dermatitis-rad-conference-reinforce-use-in-atopi" rel="noreferrer noopener">with skin of color</a>.
These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones.
The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones.
The data were shared at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference. In the trial, 120 patients with atopic dermatitis and skin of color were treated with Dupixent every two weeks using a weight-based dosing regimen.
At 24 weeks:
<ul class="wp-block-list">
<li>76% achieved a ≥75% improvement in overall disease severity (EASI-75), the primary endpoint. Some patients saw improvements as early as two weeks.</li>
<li>53% achieved clinically meaningful improvement in itch (≥4-point reduction on the peak-pruritus numerical rating scale [PP-NRS]). Improvements were seen by some patients as early as two weeks.</li>
<li>Patients experienced a 53% reduction from baseline in post-inflammatory hyperpigmentation, dropping from 5.1 points (moderate/marked) to 2.4 points (mild).</li>
<li>Based on patient reporting, 18% were very or extremely bothered by dry skin, compared to 78% at baseline.</li>
<li>The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications.</li>
</ul>
Price Action: REGN stock was trading higher by 1.53% to $500.75, and SNY stock was down 0.99% at $49.97.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45817049/arcutis-unveils-long-term-efficacy-safety-for-zoryve-cream-in-pediatric-patients-with-atopic-dermatitis" target="_blank" rel="noreferrer noopener">Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis</a></li>
</ul>
Photo by HJBC via Shutterstock

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

<ul>
<li>Atopic dermatitis is a chronic disease that disproportionately impacts communities of color</li>
<li>Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients</li>
<li>Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline</li>
<li>Results support commitment to enhance clinical understanding of chronic diseases in communities of color</li>
</ul>

Reported Saturday, Sanofi And Regeneron Present New Dupixent Results Highlighting Disease Severity Reduction In Patients With Darker Skin Tones

MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) on Thursday revealed updated data from its THIO-101 pivotal <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45790333/maia-biotechnology-announces-positive-efficacy-update-for-phase-2-thio-101-clinical-trial-in-non-s" rel="noreferrer noopener">Phase 2 clinical trial</a>.
The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">therapy and chemotherapy</a>.
As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39909095/maia-biotechnologys-lung-cancer-drug-shows-promising-long-term-benefits-in-advanced-patients" rel="noreferrer noopener">MAIA Biotechnology&#8217;s Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients</a>
The treatment has been generally well-tolerated to date in this heavily pretreated population.
At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival.
Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.
&#8220;This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,&#8221; said MAIA Chairman and CEO Vlad Vitoc.
MAIA&#8217;s multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45796236/maia-biotechnology-announces-new-responder-in-non-small-cell-lung-cancer-phase-2-clinical-trial" rel="noreferrer noopener">at least 30%</a>.
&#8220;The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,&#8221; Vitoc added.
Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45800081/dr-reddys-and-alvotech-join-hands-to-develop-biosimilar-for-mercks-blockbuster-cancer-drug">Dr Reddy&#8217;s And Alvotech Join Hands To Develop Biosimilar For Merck&#8217;s Blockbuster Cancer Drug</a></li>
</ul>
Photo via Shutterstock

MAIA

MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

UBS analyst Trung Huynh maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and lowers the price target from $633 to $560.

UBS Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $560

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework. Let's break down why this fall isn't just technical noise and what the Adhishthana Principles reveal about what lies ahead.
<h3 class="wp-block-heading">A Look Back at Regeneron's Adhishthana Cycle so far</h3>
Regeneron's current cycle began on January 29, 2018, and for much of it, the stock moved in line with Adhishthana&#8217;s expectations. The early phases were textbook examples of how market behavior follows cyclical energy, until everything changed in Phase 9.
<h4 class="wp-block-heading">Phase 2: The Rally of Buddhi</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="924" height="664" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102631/Regeneron-Adhishthana-Phase-2.png" alt="Fig.1 Regeneron Phase 2 (Source: Adhishthana.com)" class="wp-image-13854" style="width:513px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102631/Regeneron-Adhishthana-Phase-2.png 924w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102631/Regeneron-Adhishthana-Phase-2-300x216.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102631/Regeneron-Adhishthana-Phase-2-768x552.png 768w" sizes="(max-width: 924px) 100vw, 924px" /><figcaption class="wp-element-caption">Fig.1 Regeneron Phase 2 (Source: Adhishthana.com)</figcaption></figure>
During Phase 2, Regeneron consolidated tightly for exactly 37 bars, just as the Adhishthana framework anticipates. What followed was a strong Rally of Buddhi, with the stock surging approximately 113%.
<h4 class="wp-block-heading">Phase 3: The Yajya Formation</h4>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="640" height="530" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102730/Regeneron-Phase-3-Adhishthana.png" alt="Fig.2 Regeneron Phase 3 (Source: Adhishthana.com)" class="wp-image-13855" style="width:367px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102730/Regeneron-Phase-3-Adhishthana.png 640w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04102730/Regeneron-Phase-3-Adhishthana-300x248.png 300w" sizes="(max-width: 640px) 100vw, 640px" /><figcaption class="wp-element-caption">Fig.2 Regeneron Phase 3 (Source: Adhishthana.com)</figcaption></figure>
Phase 3 delivered a textbook Yajya, a slight rally followed by a rounded top and then a sharp decline. Regeneron dropped ~33%, perfectly aligning with expectations for this phase.
<h4 class="wp-block-heading">Phase 6: Discovery of the Nirvana Level</h4>
In Phase 6, Regeneron established its Nirvana Level at $671.41. This level now acts as a valuation magnet, drawing prices toward it during selling phases and serving as a benchmark throughout the remainder of the cycle.
<h3 class="wp-block-heading">The Turning Point: What Went Wrong in Regeneron&#8217;s Phase 9?</h3>
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="370" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04103103/Regeneron-Cakra-Adhishthana.png" alt="Fig.3 Regeneron Phase 9 and Cakra (Source: Adhishthana.com)" class="wp-image-13856" style="width:902px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04103103/Regeneron-Cakra-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04103103/Regeneron-Cakra-Adhishthana-300x93.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04103103/Regeneron-Cakra-Adhishthana-1024x316.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/04103103/Regeneron-Cakra-Adhishthana-768x237.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.3 Regeneron Phase 9 and Cakra (Source: Adhishthana.com)</figcaption></figure>
Typically, Phase 9 marks the supreme move, a breakout above the bullish &#8220;Cakra&#8221; consolidation channel that forms between Phases 4 to 8. This move often launches the stock into the Himalayan Ascent.
However, when a stock breaks the Cakra on the downside, it doesn't rise; it plunges.
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"When the underlying breaks the Cākra on the flip side, it typically draws consolidation up to the Guna triads. The movement after the break is typically highly significant, and the selling momentum is extremely strong. Such a move shall be called the Move of Pralayā." — Adhishthana: The Principles That Govern Wealth, Time &amp; Tragedy
</blockquote>
Regeneron did exactly that, it broke the Cakra on the flip side, triggering what I call the Move of Pralaya, a collapse of bullish structure and sentiment. Since that break, the stock has fallen by ~54%.
<h3 class="wp-block-heading">What's Next for Regeneron?</h3>
Now in Phase 10, Regeneron is stuck in structural limbo. According to Adhishthana Principles, no meaningful recovery can occur until it enters the Guna Triads, i.e, Phases 14, 15, and 16. This triad begins on February 7, 2028. Only after the completion of the triads can we assess whether the stock will rebuild momentum and attempt to reach its Nirvana, the ultimate price peak across the 18-phase cycle.
Until then, the structure suggests continued weakness and uncertainty.
<h3 class="wp-block-heading">Investor Takeaway</h3>
Regeneron's fall is not random, it's deeply rooted in a structural breakdown identified by the Adhishthana framework. The breach of the Cakra has invited the Move of Pralaya, and data shows that recovery before the Guna Triads is unlikely. Investors should avoid fresh positions at this stage. For existing holders, reevaluation is warranted, as the road to recovery may still be years away.&nbsp;

Why Regeneron Is Falling And Why You Should Avoid It

Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) has outperformed the market over the past 15 years by 9.69% on an annualized basis producing an average annual return of 21.89%. Currently, Regeneron Pharmaceuticals has a market capitalization of $52.77 billion. 
Buying $100 In REGN: If an investor had bought $100 of REGN stock 15 years ago, it would be worth $1,840.98 today based on a price of $488.79 for REGN at the time of writing.
<h3>Regeneron Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748987111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years

Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) on Monday released interim results from the ongoing Phase 2 COURAGE trial.
The company is investigating novel combinations of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegovy (semaglutide) (GLP-1 receptor agonist) and trevogrumab (anti-GDF8/anti-myostatin) with or without garetosmab <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">(anti-activin A) for obesity</a>.
The trial demonstrated:
<ul class="wp-block-list">
<li>Approximately 35% of semaglutide-induced weight loss was due to loss of lean mass</li>
<li>Combining semaglutide with trevogrumab with or without garetosmab helped preserve lean mass while <a href="https://www.benzinga.com/pressreleases/25/06/g45717752/interim-results-from-ongoing-phase-2-courage-trial-confirm-potential-to-improve-the-quality-of-sem" target="_blank" rel="noreferrer noopener">increasing loss of fat mass</a>.</li>
<li>Wegovy patients shed about 23 pounds in the study, about 7.9 pounds of which constituted lean mass.</li>
<li>The trevogrumab and low-dose Wegovy combo led to about 21.6 pounds of weight loss, with 3.7 pounds in lean mass.</li>
<li>At a higher dose, the trevogrumab combo therapy showed a weight loss of 24.8 pounds; 4.2 pounds in lean mass.</li>
<li>A triplet combination of semaglutide plus trevogrumab plus garetosmab showed a weight loss of 30 pounds and 2 pounds in lean mass.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data" rel="noreferrer noopener">Regeneron, Sanofi Stock Falls After Uneven Smoker&#8217;s Lung Drug Data</a>
The<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41208078/regeneron-chief-flags-health-risks-with-popular-weight-loss-medications-like-ozempic-says-company" rel="noreferrer noopener"> combination of semaglutide</a> with trevogrumab was generally well-tolerated; the triplet combination of semaglutide with both antibodies had a substantially higher rate of discontinuations due to tolerability issues and other adverse events, consistent with the safety profile previously seen with garetosmab alone.
After 26 weeks, patients enter into the weight-maintenance phase, receiving either higher-dose trevogrumab monotherapy or a placebo through the end of the trial (week 52).
Data from this phase are not yet available.
Regeneron also announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited. The company acquired clinical development and commercial rights outside the Chinese Mainland, Hong Kong and Macau for a dual GLP-1/GIP receptor agonist <a href="https://www.benzinga.com/pressreleases/25/06/g45717858/regeneron-expands-clinical-stage-obesity-portfolio-with-strategic-in-licensing-of-novel-dual-glp-1" target="_blank" rel="noreferrer noopener">currently in Phase 3 testing</a>.
Therapeutic candidate (HS-20094) – studied in over 1,000 patients and administered weekly subcutaneous injections – has demonstrated promising efficacy and safety clinical data, suggesting a potentially similar profile to the only FDA-approved GLP-1/GIP receptor agonist.
A Phase 3 trial in obesity in China and a Phase 2b study in diabetes are ongoing.
Regeneron will pay Hansoh $80 million upfront. The deal may include additional payments of up to $1.93 billion if certain milestones are achieved.
Potential royalties for global net sales outside designated territories would be in the low double digits.
The company says the complementary asset enables synergy and flexibility across Regeneron&#8217;s broad pipeline of obesity and metabolic programs focused on improved quality of weight loss, co-morbidities, and long-term health.
Price Action: REGN stock is down 0.24% at $489.10 at the last check on Monday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/06/45725058/loeb-rides-nvidias-ai-wave-bets-big-on-atts-telecom-comeback" target="_blank" rel="noreferrer noopener">Loeb Rides Nvidia&#8217;s AI Wave, Bets Big On AT&amp;T&#8217;s Telecom Comeback</a></li>
</ul>
Image: Shutterstock

Regeneron's Obesity Trial With Novo Nordisk's Wegovy Hits Lean Target

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Buy and lowers the price target from $700 to $650.

Citigroup Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $650

Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">STAT6 degrader medicine</a>.
The findings significantly surpassed the company&#8217;s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release.
Pharmacokinetics (PK):
KT-621 demonstrated a favorable <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45717730/kymera-therapeutics-announces-positive-first-in-human-results-from-phase-1-healthy-volunteer-clini" rel="noreferrer noopener">plasma PK profile</a> after single and multiple doses. Rapid absorption was demonstrated with a median tmax&nbsp;of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing, and a steady state was achieved by Day 4.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/06/45719840/modernas-new-covid-vaccine-secures-fda-clearance-for-seniors-at-risk-individuals" rel="noreferrer noopener">Moderna&#8217;s New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals</a>
Pharmacodynamics (PD):
KT-621 demonstrated rapid, deep, and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
STAT6 levels in blood and skin were measured. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or, when most subjects&#8217; STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both.
In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching &gt;90% across all SAD doses starting at 6.25 mg.
All SAD cohorts at 75 mg or greater doses achieved &gt;95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects.
In MAD, STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg.
Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg, with recovery starting as early as 4 days after the last dose.
In MAD, robust STAT6 degradation was observed in the skin at the first timepoint measured (Day 7) for doses above 1.5 mg.
Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg.
Th2 Biomarkers:
TARC reduction was observed for all KT-621 dose groups, with a median reduction of up to 37% at Day 14.
The company says the results are comparable or superior to what was seen in the Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>)/Regeneron Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Dupixent (dupilumab) healthy volunteer study.
The safety profile of KT-621 was undifferentiated from that of the placebo.
The company&#8217;s KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected to be reported in the fourth quarter of 2025. 
Two parallel Phase 2b trials in atopic dermatitis and asthma will start in 4Q25 and 1Q26, respectively.
Price Action: KYMR stock was trading higher by 30.2% to $38.58 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45720783/kidney-health-focused-vera-therapeutics-stock-price-spikes-on-heels-of-successful-trial-data" target="_blank" rel="noreferrer noopener">Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data</a></li>
</ul>
Photo via Shutterstock

KYMR

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

BMO Capital analyst Evan David Seigerman maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $800 to $600.

BMO Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $600

Press Releases

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

Investor Alert: Johnson Fistel Investigates Regeneron Pharmaceuticals, Integral Ad Science, Manhattan Associates, and Crocs on Behalf of Shareholders

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

ANIX

CROX

IBRX

IOVA

MANH

ONCY

PARIS:SAN

TSX:ONC

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Regeneron Pharmaceuticals

Noticias

Últimas noticias sobre Regeneron Pharmaceuticals (NASDAQ:REGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL